# HER2-Peptide Vaccination of Patients With Solid Tumors

> **NCT02276300** · PHASE1 · COMPLETED · sponsor: **Technical University of Munich** · enrollment: 2 (actual)

## Conditions studied

- Gastric Cancer
- Breast Cancer

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Sargramostim
- **DRUG:** HER2-Peptid-Vakzine
- **DRUG:** Imiquimod

## Key facts

- **NCT ID:** NCT02276300
- **Lead sponsor:** Technical University of Munich
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2017-07-18
- **Final completion:** 2018-07-13
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2019-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02276300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02276300, "HER2-Peptide Vaccination of Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02276300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*